financetom
Business
financetom
/
Business
/
Crocs Remains a 'Low Growth' Stock Despite Q4 Beats, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crocs Remains a 'Low Growth' Stock Despite Q4 Beats, UBS Says
Feb 19, 2025 12:36 PM

03:11 PM EST, 02/19/2025 (MT Newswires) -- Crocs ( CROX ) remains a "low growth" stock despite Q4 earnings that were "moderately better than expected," UBS Securities said Wednesday in a report.

Last week, Crocs ( CROX ) posted Q4 adjusted earnings of $2.52 per diluted share on revenue of $989.8 million. Analysts polled by FactSet expected EPS of $2.26 on sales of $961.6 million.

The Q4 results weren't a "thesis changer," and 2025 guidance implies a slowdown in the brand's North American growth rate, UBS said.

UBS forecast a 1% EPS compound annual growth rate for five years and doesn't see a catalyst to drive the stock's price-to-earnings ratio higher.

The company "would need its Crocs brand to show accelerating sales growth in North America, but we doubt this happens" in the next 12 months, the report said.

UBS raised its price target on Crocs ( CROX ) stock to $132 from $122 and kept its neutral rating.

Shares of Crocs ( CROX ) rose 1.9% in recent Wednesday trading.

Price: 109.34, Change: +1.99, Percent Change: +1.85

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
Jul 22, 2025
July 22 (Reuters) - Shares of Sarepta Therapeutics ( SRPT ) fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Mercurity Fintech Launches $10 Million Share Repurchase Program
Mercurity Fintech Launches $10 Million Share Repurchase Program
Jul 22, 2025
09:34 AM EDT, 07/22/2025 (MT Newswires) -- Mercurity Fintech ( MFH ) said Tuesday it is launching a share repurchase program of up to $10 million over the next 12 months. The repurchase program may be suspended or discontinued at any time at its discretion, the company said. Price: 2.30, Change: +0.10, Percent Change: +4.68 ...
Essential Utilities Unit Completes Purchase of City of Beaver Falls Wastewater System
Essential Utilities Unit Completes Purchase of City of Beaver Falls Wastewater System
Jul 22, 2025
09:26 AM EDT, 07/22/2025 (MT Newswires) -- Essential Utilities ( WTRG ) said Tuesday its Aqua Pennsylvania unit has completed a $37.75 million purchase of the City of Beaver Falls wastewater system in Beaver County, Pennsylvania. The system serves 3,200 clients in the City of Beaver Falls and the wastewater system provides bulk transmission and treatment service for 3,800 equivalent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved